There are now two COVID-19 vaccine candidates that look very promising. Late-stage clinical trials suggest they may be more than 90 per cent effective. The Canadian government has signed deals with both manufacturers, so if they’re approved by Health Canada, experts say they should be available to us sometime next year. But a new vaccine naturally raises lots of questions, from its safety profile to who will get it first in a country of more than 37 million people. Dr. Jeff Kwong, interim director of the Centre for Vaccine Preventable Diseases at the University of Toronto, gives us some answers.
